Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Completed
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/07/2020
Locations: New York University Medical Center, New York, New York +1 locations
Conditions: Acute Lymphoblastic Leukemia
Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty
Withdrawn
The purpose of this study is to compare the efficacy and duration of pain relief after total knee arthroplasty provided by a single injection of liposomal bupivacaine (EXPAREL®) versus standard bupivacaine with an adjuvant, dexamethasone when administered as a quadriceps sparing femoral nerve block and periarticular injection. It is hypothesized that liposomal bupivacaine is superior to standard bupivacaine with dexamethasone and will decrease time to discharge readiness.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
01/22/2020
Locations: Albany Medical Center, Albany, New York
Conditions: Osteoarthritis, Pain, Postoperative
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Completed
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Columbia University, New York, New York
Conditions: Multiple Myeloma
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Terminated
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2019
Locations: Memorial Sloan-Kettering, New York, New York
Conditions: Acute Lymphoblastic Leukemia
A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
Recruiting
To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
12/17/2019
Locations: Ophthalmic Consultants of Long Island, Garden City, New York
Conditions: Patient Preference
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/07/2019
Locations: Not set, New York, New York +1 locations
Conditions: Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Completed
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Arena Oncology Associates, PC, Lake Success, New York
Conditions: Multiple Myeloma
Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.
Completed
The purpose of this study is to determine if there is a difference in patient outcomes with general anesthesia versus spinal anesthesia when given in addition to popliteal and adductor canal nerve blocks for foot and ankle surgery. Popliteal and adductor canal nerve blocks are injections of local anesthetic agents near nerves in the back and front of the knee going to the foot and ankle that provide numbness during and after surgery. These peripheral nerve blocks offer good pain control and redu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2019
Locations: Hospital for Special Surgery, New York, New York, New York
Conditions: Nerve Block, General Anesthesia, Spinal Anesthesia, Pain, Postoperative Nausea and Vomiting
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed
RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in treating patients who have relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/15/2019
Locations: St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections
Completed
Patients who present for scheduled (non-emergent) cesarean section will be given either intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal anesthetic. The investigators will then compare the incidence of nausea and vomiting and the use of rescue anti-nausea medications in both groups. Our hypothesis is that patients receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section will have a significantly lower incidence and severity... Read More
Gender:
FEMALE
Ages:
Between 18 years and 46 years
Trial Updated:
10/04/2019
Locations: Weill Cornell Medical College, New York, New York
Conditions: Postoperative Nausea and Vomiting
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/28/2019
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Completed
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/22/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Large-Cell, Diffuse